Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Why and how to assess older people with cancer?].
Helissey C, Geiss R, Baldini C, Noret A, Frelaut M, Rodrigues M, Bringuier M. Helissey C, et al. Among authors: rodrigues m. Bull Cancer. 2021 May;108(5):513-520. doi: 10.1016/j.bulcan.2021.01.011. Epub 2021 Apr 6. Bull Cancer. 2021. PMID: 33836861 Review. French.
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y. Loap P, et al. Among authors: rodrigues m. JAMA Oncol. 2022 Dec 1;8(12):1802-1808. doi: 10.1001/jamaoncol.2022.5074. JAMA Oncol. 2022. PMID: 36301572 Free PMC article. Clinical Trial.
A call for specific geriatric data on cervical cancers.
Rodrigues MJ, Zapardiel I, Frélaut M, Brain E, Falandry C. Rodrigues MJ, et al. Future Oncol. 2016 May;12(9):1101-4. doi: 10.2217/fon-2016-0022. Epub 2016 Mar 9. Future Oncol. 2016. PMID: 26955977 No abstract available.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P. Carvajal RD, et al. Among authors: rodrigues mj. J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. J Clin Oncol. 2018. PMID: 29528792 Free article. Clinical Trial.
[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer].
Bay JO, André T, Caux C, Evrard S, Gonçalves A, L'Allemain G, Magné N, Orbach D, Penel N, Rodrigues M, Thariat J, Thiery-Vuillemin A, Wislez M; Comité de Rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: rodrigues m. Bull Cancer. 2019 Jan;106(1):12-23. doi: 10.1016/j.bulcan.2018.12.005. Epub 2019 Jan 3. Bull Cancer. 2019. PMID: 30612698 Review. French.
[Editorial of the French Society of Cancer].
Rodrigues M; et l'ensemble des membres du Bureau de la Société Française du Cancer. Rodrigues M, et al. Bull Cancer. 2019 Jan;106(1):4. doi: 10.1016/j.bulcan.2019.01.003. Bull Cancer. 2019. PMID: 30709566 French. No abstract available.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
4,610 results